Back

바이오톡스텍 KOSDAQ

086040

Suggest a tag

Watch

Notes Naver Finance

Upcoming shareholder meeting

Extraordinary

2026.11.03 DART

Meeting date 2026.12.16 09:00 Location 충청북도 청주시 청원구 오창읍 연구단지로 53 본사

• 제1호 의안: 이사 선임의 건
• 제1-1호 의안: 독립이사 이정환 선임의 건
• 제2호 의안: 자본준비금의 이익잉여금 전입의 건

Meeting voting results

Previous meeting results

Financial indicators

Market cap

338 × 100M KRW

Approx. 326 × 100M KRW excluding treasury shares

PBR

1.00

PER

ROE

2.90%

Dividend yield

Debt-to-equity ratio

312.2%

Share price history

Share price

Daily close

Latest close

5-year high

5-year low

Use the period buttons above to adjust the range.

Shareholder distribution

Based on 2026 First-quarter report (2026-03-31)

Controlling shareholders total

23.44%

Minority shareholders (excl. related parties)

61.00%

Large outside holders (1%+)

12.10% (11 people)

Treasury shares

3.46%

Total shareholders

13,698 people

Annual earnings Trend

Financial statements

Consolidated · includes subsidiaries

바이오톡스텍 — Annual Consolidated Financial statements
Item	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Income statement
Revenue	172.7 × 100M KRW	150.9 × 100M KRW	166.8 × 100M KRW	222.6 × 100M KRW	255.6 × 100M KRW	325.8 × 100M KRW	258.5 × 100M KRW	264.3 × 100M KRW	340.9 × 100M KRW	372.9 × 100M KRW	326.3 × 100M KRW	413.4 × 100M KRW	470.2 × 100M KRW
Operating profit	-18.3 × 100M KRW	-46.5 × 100M KRW	-37 × 100M KRW	22 × 100M KRW	21.9 × 100M KRW	16.5 × 100M KRW	-1.3 × 100M KRW	5.4 × 100M KRW	41.6 × 100M KRW	8 × 100M KRW	-81.9 × 100M KRW	-88.8 × 100M KRW	-48.1 × 100M KRW
Net income	-5.6 × 100M KRW	-48.9 × 100M KRW	-37.1 × 100M KRW	11.6 × 100M KRW	11.8 × 100M KRW	34.9 × 100M KRW	-17.1 × 100M KRW	23.7 × 100M KRW	69.8 × 100M KRW	15.1 × 100M KRW	-89.5 × 100M KRW	-126.6 × 100M KRW	-15.7 × 100M KRW
Operating margin	-10.60%	-30.80%	-22.19%	9.90%	8.55%	5.08%	-0.51%	2.03%	12.20%	2.15%	-25.09%	-21.48%	-10.23%
Balance sheet
Total assets	462.9 × 100M KRW	478.4 × 100M KRW	453.8 × 100M KRW	480.1 × 100M KRW	597.7 × 100M KRW	631.4 × 100M KRW	601.8 × 100M KRW	636.5 × 100M KRW	907.4 × 100M KRW	1,257 × 100M KRW	1,470.4 × 100M KRW	1,361.9 × 100M KRW	1,316.1 × 100M KRW
Total liabilities	206.9 × 100M KRW	211.5 × 100M KRW	217.9 × 100M KRW	224.4 × 100M KRW	285.3 × 100M KRW	273.9 × 100M KRW	289.8 × 100M KRW	293.7 × 100M KRW	488.9 × 100M KRW	813.3 × 100M KRW	988 × 100M KRW	1,016.7 × 100M KRW	996.8 × 100M KRW
Total equity	256 × 100M KRW	266.8 × 100M KRW	235.8 × 100M KRW	255.6 × 100M KRW	312.4 × 100M KRW	357.5 × 100M KRW	312 × 100M KRW	342.8 × 100M KRW	418.5 × 100M KRW	443.7 × 100M KRW	482.3 × 100M KRW	345.3 × 100M KRW	319.3 × 100M KRW
Cash flow statement
Operating cash flow	-	-	-	-	-	-	-	-	-	-	-	-71.2 × 100M KRW	66.4 × 100M KRW
Investing cash flow	-	-	-	-	-	-	-	-	-	-	-	-98.4 × 100M KRW	61.8 × 100M KRW
Financing cash flow	-	-	-	-	-	-	-	-	-	-	-	7.6 × 100M KRW	-54.9 × 100M KRW
Investment indicators
ROE	-2.17%	-18.34%	-15.73%	4.54%	3.76%	9.75%	-5.47%	6.90%	16.68%	3.41%	-18.56%	-36.66%	-4.93%
Debt-to-equity ratio	80.84%	79.27%	92.41%	87.80%	91.32%	76.61%	92.90%	85.68%	116.83%	183.32%	204.83%	294.47%	312.16%
Separate total assets	-	-	-	-	-	-	-	-	-	-	-	-	-
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-
PER	-	-	-	-	-	-	-	-	-	-	-	-	-
PBR	-	-	-	-	-	-	-	-	-	-	-	-	-
Dividend per share	-	-	-	-	-	-	-	-	-	-	-	-	-
Detailed accounts
Current assets	-	-	135.5 × 100M KRW	-	-	158.6 × 100M KRW	-	-	377.5 × 100M KRW	-	-	589.2 × 100M KRW	486.1 × 100M KRW
Non-current assets	-	-	318.3 × 100M KRW	-	-	472.7 × 100M KRW	-	-	529.9 × 100M KRW	-	-	772.7 × 100M KRW	829.9 × 100M KRW
Current liabilities	-	-	191.4 × 100M KRW	-	-	238.7 × 100M KRW	-	-	457.8 × 100M KRW	-	-	822.1 × 100M KRW	854.9 × 100M KRW
Non-current liabilities	-	-	26.6 × 100M KRW	-	-	35.2 × 100M KRW	-	-	31.1 × 100M KRW	-	-	194.6 × 100M KRW	141.8 × 100M KRW
Equity attributable to owners	-	-	-	-	-	-	-	-	-	-	-	400.8 × 100M KRW	401.6 × 100M KRW
Share capital	-	-	72.1 × 100M KRW	-	-	72.8 × 100M KRW	-	-	73.3 × 100M KRW	-	-	79.8 × 100M KRW	79.8 × 100M KRW
Capital surplus	-	-	-	-	-	-	-	-	-	-	-	325.2 × 100M KRW	325.2 × 100M KRW
Other equity	-	-	-	-	-	-	-	-	-	-	-	-4.7 × 100M KRW	-15 × 100M KRW
Retained earnings	-	-	-45.9 × 100M KRW	-	-	17.6 × 100M KRW	-	-	93.5 × 100M KRW	-	-	5,856 × 10,000 KRW	11.6 × 100M KRW
Non-controlling interests	-	-	-	-	-	-	-	-	-	-	-	-55.6 × 100M KRW	-82.3 × 100M KRW

ROE is net income divided by closing equity. PER and PBR are omitted when the accounting scope or price date is unverified.

바이오톡스텍 — Quarterly Consolidated Financial statements
Item	26/3
Income statement
Revenue	118.7 × 100M KRW
Operating profit	-18.2 × 100M KRW
Net income	-27.1 × 100M KRW
Operating margin	-15.35%
Balance sheet
Total assets	1,300.6 × 100M KRW
Total liabilities	1,008.1 × 100M KRW
Total equity	292.5 × 100M KRW
Cash flow statement
Operating cash flow	6 × 100M KRW
Investing cash flow	-24 × 100M KRW
Financing cash flow	-15.1 × 100M KRW
Investment indicators
Debt-to-equity ratio	344.69%
EPS	-
Detailed accounts
Current assets	461.2 × 100M KRW
Non-current assets	839.4 × 100M KRW
Current liabilities	874.4 × 100M KRW
Non-current liabilities	133.7 × 100M KRW
Equity attributable to owners	383 × 100M KRW
Share capital	79.8 × 100M KRW
Capital surplus	325.2 × 100M KRW
Other equity	-14.9 × 100M KRW
Retained earnings	-7.1 × 100M KRW
Non-controlling interests	-90.5 × 100M KRW

Income figures cover the quarter, not the year to date. Balance sheet figures are quarter-end balances.

Quarterly cash flow is calculated from changes in cumulative totals.

ROE is net income divided by closing equity. PER and PBR are omitted when the accounting scope or price date is unverified.

Separate · this company only

바이오톡스텍 — Annual Separate Financial statements
Item	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Income statement
Revenue	170.7 × 100M KRW	142.1 × 100M KRW	148.4 × 100M KRW	203 × 100M KRW	223.5 × 100M KRW	241.1 × 100M KRW	243.3 × 100M KRW	254 × 100M KRW	326.7 × 100M KRW	372.9 × 100M KRW	304.6 × 100M KRW	333.9 × 100M KRW	330.2 × 100M KRW
Operating profit	-9.1 × 100M KRW	-35.8 × 100M KRW	-39.4 × 100M KRW	16.2 × 100M KRW	22.4 × 100M KRW	16.8 × 100M KRW	4,520 × 10,000 KRW	10.8 × 100M KRW	49.5 × 100M KRW	38.1 × 100M KRW	-13.7 × 100M KRW	-31.8 × 100M KRW	-15.1 × 100M KRW
Net income	4 × 100M KRW	-38.9 × 100M KRW	-39 × 100M KRW	8.3 × 100M KRW	14.8 × 100M KRW	36 × 100M KRW	-14.1 × 100M KRW	20.2 × 100M KRW	59.1 × 100M KRW	39.4 × 100M KRW	-17.9 × 100M KRW	-18.8 × 100M KRW	36.5 × 100M KRW
Operating margin	-5.31%	-25.20%	-26.57%	8.00%	10.01%	6.99%	0.19%	4.26%	15.14%	10.21%	-4.48%	-9.53%	-4.58%
Balance sheet
Total assets	458.4 × 100M KRW	483.3 × 100M KRW	454.9 × 100M KRW	479 × 100M KRW	539.3 × 100M KRW	579.1 × 100M KRW	605.8 × 100M KRW	637.1 × 100M KRW	882.5 × 100M KRW	943.1 × 100M KRW	923.6 × 100M KRW	928.2 × 100M KRW	950 × 100M KRW
Total liabilities	209.4 × 100M KRW	208.4 × 100M KRW	215 × 100M KRW	222.6 × 100M KRW	262.8 × 100M KRW	256.1 × 100M KRW	291 × 100M KRW	296.2 × 100M KRW	479.7 × 100M KRW	499.7 × 100M KRW	377.2 × 100M KRW	414.2 × 100M KRW	411 × 100M KRW
Total equity	249 × 100M KRW	274.9 × 100M KRW	239.9 × 100M KRW	256.5 × 100M KRW	276.6 × 100M KRW	323 × 100M KRW	314.8 × 100M KRW	340.9 × 100M KRW	402.9 × 100M KRW	443.4 × 100M KRW	546.4 × 100M KRW	514 × 100M KRW	539 × 100M KRW
Cash flow statement
Operating cash flow	-	-	-	-	-	-	-	-	-	-	-	15 × 100M KRW	-2.7 × 100M KRW
Investing cash flow	-	-	-	-	-	-	-	-	-	-	-	-91.6 × 100M KRW	63.1 × 100M KRW
Financing cash flow	-	-	-	-	-	-	-	-	-	-	-	8.7 × 100M KRW	-14.4 × 100M KRW
Investment indicators
ROE	1.60%	-14.17%	-16.26%	3.24%	5.33%	11.15%	-4.48%	5.91%	14.67%	8.88%	-3.28%	-3.67%	6.78%
Debt-to-equity ratio	84.08%	75.82%	89.60%	86.79%	95.01%	79.28%	92.43%	86.88%	119.07%	112.71%	69.04%	80.57%	76.25%
Separate total assets	-	-	-	-	-	-	-	-	-	-	-	-	-
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-
PER	-	-	-	-	-	-	-	-	-	-	-	-	-
PBR	-	-	-	-	-	-	-	-	-	-	-	-	-
Dividend per share	-	-	-	-	-	-	-	-	-	-	-	-	-
Detailed accounts
Current assets	-	-	117.4 × 100M KRW	-	-	130.2 × 100M KRW	-	-	356.5 × 100M KRW	-	-	396.6 × 100M KRW	333.2 × 100M KRW
Non-current assets	-	-	337.5 × 100M KRW	-	-	448.9 × 100M KRW	-	-	526.1 × 100M KRW	-	-	531.5 × 100M KRW	616.8 × 100M KRW
Current liabilities	-	-	192.6 × 100M KRW	-	-	228.9 × 100M KRW	-	-	455.4 × 100M KRW	-	-	383.2 × 100M KRW	383.5 × 100M KRW
Non-current liabilities	-	-	22.3 × 100M KRW	-	-	27.2 × 100M KRW	-	-	24.2 × 100M KRW	-	-	31 × 100M KRW	27.5 × 100M KRW
Share capital	-	-	72.1 × 100M KRW	-	-	72.8 × 100M KRW	-	-	73.3 × 100M KRW	-	-	79.8 × 100M KRW	79.8 × 100M KRW
Capital surplus	-	-	-	-	-	-	-	-	-	-	-	325.2 × 100M KRW	325.2 × 100M KRW
Other equity	-	-	-	-	-	-	-	-	-	-	-	21.9 × 100M KRW	11 × 100M KRW
Retained earnings	-	-	-30.4 × 100M KRW	-	-	32.2 × 100M KRW	-	-	92.2 × 100M KRW	-	-	87.1 × 100M KRW	123.1 × 100M KRW

ROE is net income divided by closing equity. PER and PBR are omitted when the accounting scope or price date is unverified.

바이오톡스텍 — Quarterly Separate Financial statements
Item	26/3
Income statement
Revenue	74.3 × 100M KRW
Operating profit	-9.9 × 100M KRW
Net income	-10.8 × 100M KRW
Operating margin	-13.31%
Balance sheet
Total assets	959.3 × 100M KRW
Total liabilities	431.1 × 100M KRW
Total equity	528.2 × 100M KRW
Cash flow statement
Operating cash flow	20.3 × 100M KRW
Investing cash flow	-23.2 × 100M KRW
Financing cash flow	-2.4 × 100M KRW
Investment indicators
Debt-to-equity ratio	81.61%
EPS	-
Detailed accounts
Current assets	329.1 × 100M KRW
Non-current assets	630.2 × 100M KRW
Current liabilities	399.3 × 100M KRW
Non-current liabilities	31.7 × 100M KRW
Share capital	79.8 × 100M KRW
Capital surplus	325.2 × 100M KRW
Other equity	11 × 100M KRW
Retained earnings	112.3 × 100M KRW

Income figures cover the quarter, not the year to date. Balance sheet figures are quarter-end balances.

Quarterly cash flow is calculated from changes in cumulative totals.

ROE is net income divided by closing equity. PER and PBR are omitted when the accounting scope or price date is unverified.

Legacy summaries and estimates; may include data with unverified accounting scope.

바이오톡스텍 — Annual Legacy summary & estimates Financial statements
Item	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023 Consolidated	2024 Consolidated	2025 Consolidated
Income statement
Revenue	172.7 × 100M KRW	150.9 × 100M KRW	166.8 × 100M KRW	222.6 × 100M KRW	255.6 × 100M KRW	325.8 × 100M KRW	258.5 × 100M KRW	264.3 × 100M KRW	340.9 × 100M KRW	372.9 × 100M KRW	326.3 × 100M KRW	413.4 × 100M KRW	470.2 × 100M KRW
Operating profit	-18.3 × 100M KRW	-46.5 × 100M KRW	-37 × 100M KRW	22 × 100M KRW	21.9 × 100M KRW	16.5 × 100M KRW	-1.3 × 100M KRW	5.4 × 100M KRW	41.6 × 100M KRW	8 × 100M KRW	-81.9 × 100M KRW	-88.8 × 100M KRW	-48.1 × 100M KRW
Net income	-5.6 × 100M KRW	-48.9 × 100M KRW	-37.1 × 100M KRW	11.6 × 100M KRW	11.8 × 100M KRW	34.9 × 100M KRW	-17.1 × 100M KRW	23.7 × 100M KRW	69.8 × 100M KRW	15.1 × 100M KRW	-89.5 × 100M KRW	-126.6 × 100M KRW	-15.7 × 100M KRW
Operating margin	-10.60%	-30.80%	-22.19%	9.90%	8.55%	5.08%	-0.51%	2.03%	12.20%	2.15%	-25.09%	-21.48%	-10.23%
Balance sheet
Total assets	-	-	-	-	-	-	-	-	-	-	1,470.4 × 100M KRW	1,361.9 × 100M KRW	1,316.1 × 100M KRW
Total liabilities	206.9 × 100M KRW	211.5 × 100M KRW	217.9 × 100M KRW	224.4 × 100M KRW	285.3 × 100M KRW	273.9 × 100M KRW	289.8 × 100M KRW	293.7 × 100M KRW	488.9 × 100M KRW	813.3 × 100M KRW	988 × 100M KRW	1,016.7 × 100M KRW	996.8 × 100M KRW
Total equity	256 × 100M KRW	266.8 × 100M KRW	235.8 × 100M KRW	255.6 × 100M KRW	312.4 × 100M KRW	357.5 × 100M KRW	312 × 100M KRW	342.8 × 100M KRW	418.5 × 100M KRW	443.7 × 100M KRW	482.3 × 100M KRW	345.3 × 100M KRW	319.3 × 100M KRW
Investment indicators
ROE	-2.17%	-18.34%	-15.73%	4.54%	3.76%	9.75%	-5.47%	6.90%	16.68%	3.41%	-18.56%	-36.66%	-4.93%
Debt-to-equity ratio	80.84%	79.27%	92.41%	87.80%	91.32%	76.61%	92.90%	85.68%	116.83%	183.32%	204.83%	294.47%	312.16%
Separate total assets	-	-	-	-	-	-	-	-	-	-	923.6 × 100M KRW	928.2 × 100M KRW	950 × 100M KRW
EPS	-	-	-	-	-	-	-	-	-	KRW 186	KRW -316	KRW -403	KRW 73
PER	-	-	-	-	-	-	-	-	-	43.81×	-19.52×	-8.28×	38.63×
PBR	-	-	-	-	-	-	-	-	-	2.69	1.90	1.31	1.08
Dividend per share	-	-	-	-	-	-	-	-	-	-	-	-	-

바이오톡스텍 — Quarterly Legacy summary & estimates Financial statements
Item	24/3	24/6	24/9	24/12 Consolidated	25/3	25/6	25/9	25/12 Consolidated	26/3	26/6
Income statement
Revenue	89.9 × 100M KRW	98.1 × 100M KRW	111.2 × 100M KRW	-	112.5 × 100M KRW	96.2 × 100M KRW	119 × 100M KRW	-	118.7 × 100M KRW	144.6 × 100M KRW
Operating profit	-25.4 × 100M KRW	-29.1 × 100M KRW	-20.3 × 100M KRW	-	-14.2 × 100M KRW	-19.3 × 100M KRW	-13.6 × 100M KRW	-	-18.2 × 100M KRW	-1.8 × 100M KRW
Net income	-26 × 100M KRW	-32.3 × 100M KRW	-28.7 × 100M KRW	-	-20.6 × 100M KRW	-20 × 100M KRW	44.6 × 100M KRW	-	-27.1 × 100M KRW	-68.9 × 100M KRW
Operating margin	-28.22%	-29.61%	-18.26%	-	-12.63%	-20.04%	-11.46%	-	-15.35%	-1.26%
Balance sheet
Total assets	1,439.2 × 100M KRW	1,366.9 × 100M KRW	1,468.6 × 100M KRW	1,361.9 × 100M KRW	1,335.2 × 100M KRW	1,307.6 × 100M KRW	1,324.5 × 100M KRW	1,316.1 × 100M KRW	1,300.6 × 100M KRW	1,323.5 × 100M KRW
Total liabilities	982 × 100M KRW	942.8 × 100M KRW	1,082.3 × 100M KRW	1,016.7 × 100M KRW	1,010 × 100M KRW	1,002 × 100M KRW	983.9 × 100M KRW	996.8 × 100M KRW	1,008.1 × 100M KRW	1,099.7 × 100M KRW
Total equity	457.3 × 100M KRW	424.1 × 100M KRW	386.3 × 100M KRW	345.3 × 100M KRW	325.2 × 100M KRW	305.7 × 100M KRW	340.6 × 100M KRW	319.3 × 100M KRW	292.5 × 100M KRW	223.8 × 100M KRW
Investment indicators
Debt-to-equity ratio	214.76%	222.31%	280.19%	294.47%	310.54%	327.82%	288.88%	312.16%	344.69%	491.29%
EPS	-	-	-	-	-	-	-	-	-	-

Income figures cover the quarter, not the year to date. Balance sheet figures are quarter-end balances.

Property holdings

Property data is not available yet.

Ownership structure

Listed subsidiary stake value 49 × 100M KRW (Sum of market cap × ownership)

Is a listed company shown as unlisted?

Corporate shareholders

Corporate and institutional holders identified in collected disclosures. This is not a complete shareholder register. Reporting-group holdings may overlap with individual holdings.

Business report analysis

Analysis date 2026.05.25 23:46 | Based on 2025 Annual report

Unverified Original business report

사업 개요

바이오톡스텍은 의약품, 농약, 식품, 화장품, 생활용품 및 화학물질 등의 안전성·유효성 평가를 주업으로 하는 비임상 CRO 기업입니다.
2000년 설립되었으며, 2008년까지 최첨단 비임상시험 연구기반시설을 완공해 바이오 인프라 기업으로 사업 기반을 확보했습니다.

주요 매출원

별도 기준 매출액은 제26기 약 330억원, 연결 기준 매출액은 약 470억원입니다.
영업보고서 본문은 비임상 안전성평가를 주된 사업으로 설명하며, 신물질 개발사업, 자회사 및 계열회사를 통한 영장류 안전성·유효성 평가사업, 생체치료 분석사업, 동물·시약 판매사업 등으로 사업영역을 확대하고 있다고 기재합니다.

원가 구조 / 비용 특성

별도 기준 제26기 매출원가는 약 272억원으로 매출원가율은 약 82.4%입니다. 별도 영업손실은 약 15억원으로, 제25기 영업손실 약 32억원 대비 손실 폭이 축소되었습니다.
연결 기준 제26기 매출원가는 약 411억원으로 매출원가율은 약 87.5%입니다. 연결 영업손실은 약 48억원으로, 제25기 영업손실 약 89억원 대비 개선되었습니다.

자회사

(주)키프라임리서치: 영장류 안전성 및 유효성 평가. 바이오톡스텍이 49.07%를 보유한 자회사입니다.
(주)키프론바이오: 생체시료분석, 유효성평가, 동물·시약판매. 바이오톡스텍이 9.00%를 보유한 계열회사입니다.

차입 구조

주요 채권자는 산업은행 약 79억원, 국민은행 약 20억원, 하나은행 약 26억원, 신주인수권부사채권자 약 120억원입니다.

Employees

241 people

Subsidiaries

1 items

Material subsequent events

해당사항 없습니다.

Articles of incorporation analysis

Analysis date 2026.07.06 14:25 | Last amended 2025.03.28

Unverified Original articles of incorporation

주주친화

동등배당: 유상증자, 무상증자 및 주식배당으로 발행한 신주의 배당기산일을 직전 영업연도 말로 본다 (제10조의3)

주주비친화

집중투표제 명시적 배제: 2인 이상 이사를 선임하는 경우 상법 제382조의2 집중투표제를 적용하지 않아 소수주주의 이사 선임 수단을 제한한다 (제31조④)
이사 해임 가중결의: 이사 해임은 출석 주주 의결권 3분의 2 이상 및 발행주식총수 2분의 1 이상을 요구해 일반 특별결의보다 해임 장벽을 높인다 (제31조③)
적대적 M&A 관련 초다수결의제: 적대적 기업인수·합병 이후 이사·감사 해임, 신규 선임, 정관 개정에 출석 의결권 4분의 3 이상 및 발행주식총수 3분의 2 이상을 요구한다 (제28조②)
이사회 결의만으로 500억원 전환사채 제3자 배정: 주주 외의 자에게 전환사채를 발행할 수 있어 경영권 분쟁 시 우호지분 확보 수단이 될 수 있다 (제15조)
이사회 결의만으로 500억원 신주인수권부사채 제3자 배정: 주주 외의 자에게 신주인수권부사채를 발행할 수 있어 기존 주주 지분 희석 위험이 있다 (제16조)
이사 임기 3년 고정: 이사 임기를 상법상 최장 수준인 3년으로 정한다 (제32조①)
이사 책임감경 조항: 최근 1년 보수액의 6배, 사외이사는 3배를 초과하는 손해배상책임을 면제할 수 있어 주주대표소송의 실효성을 낮출 수 있다 (제35조의2)

기타 주목 조항

신주 제3자 배정: 경영상 필요, 긴급 자금조달, 기술제휴 등 사유로 발행주식총수 20% 범위 내에서 주주 외의 자에게 신주를 배정할 수 있고, 일반공모·외국인투자는 50% 범위까지 가능하다 (제10조, 제10조의1)
전환·상환우선주: 우선주 총수는 5,000,000주이며, 이사회 결의로 상환주식 또는 주주 청구에 따라 보통주식으로 전환되는 전환주식을 발행할 수 있다 (제8조)
주식매수선택권: 주주총회 특별결의로 발행주식총수의 15% 범위, 이사회 결의로 3% 범위 내에서 부여할 수 있다 (제10조의2)

Board of directors

Number of directors

3–7 people

Director term

3 years (Fixed)

Remaining term for replacements

Staggered board

None

Cumulative voting

Separate chair and CEO

Gender diversity requirement

Director liability limitation

Exemption above 6.0×

Auditors

Number of auditors

1–3 people

Auditor term

3 years (Fixed)

Shareholder meetings and dividends

Meeting notice period

14 days

Written voting

Electronic voting

Dividend record date

매 결산기말 현재(사업연도 말은 12월 31일)

Third-party allotment limit by board resolution alone

Convertible bonds (CB)

500 × 100M KRW

Bonds with warrants (BW)

500 × 100M KRW

Compensation basis

Director: 이사의 보수는 주주총회 결의로 정한다.
Auditors: 감사 보수는 제35조를 준용하되, 감사 보수 결정 의안은 이사 보수 결정 의안과 구분하여 상정·의결한다.
Retirement payments: 이사 퇴직금은 주주총회 결의를 거친 임원퇴직금지급규정에 의한다.

Executive compensation

Based on 2025 Annual report

Total compensation

9 × 100M KRW

Executives

4 people

Average per executive

2 × 100M KRW

Total dividends

Compensation / dividends

No dividend

Controlling shareholders

Name	Relationship	Age	Ownership
강종구	Self	Age 71	12.76%
키프론바이오	관계기업	-	8.48%
윤석천	친척	-	0.99%
강경애	친척	-	0.32%
이명정	친척	-	0.16%
정수용	임원	Age 53	0.13%
김동일	계열사임원	-	0.10%
강석모	자녀	-	0.09%
강일모	자녀	-	0.08%
박선희	임원	Age 52	0.01%

Holders of 5% or more

Holder	Holding ratio	Shares held	Change in ownership	Reason for filing	Report type	Filing date
강종구	24.03%	3,859,019	+0.06%	- 특별관계자 장내매수에 따른 보유주식 변동	일반	2026-08-06
강종구	23.97%	3,848,925	+0.01%	- 특별관계자 장내매수에 따른 보유주식 변동	일반	2026-08-03
강종구	23.96%	3,848,187	+0.03%	- 특별관계자 장내매수에 따른 보유주식 변동	일반	2026-07-29
강종구	23.93%	3,843,882	0.00%	- 주식보유등에 관한 계약 변경	일반	2026-03-06
강종구	23.93%	3,843,882	+0.12%	- 특별관계자 장내매수에 따른 보유주식 변동	일반	2026-02-09
강종구	23.81%	3,824,080	+0.14%	- 특별관계자 장내매수에 따른 보유주식 변동	일반	2026-01-22
강종구	23.67%	3,801,499	+0.05%	- 특별관계자 장내매수에 따른 보유주식 변동	일반	2026-01-15
강종구	23.62%	3,794,224	+0.02%	- 특별관계자 장내매수에 따른 보유주식 변동	일반	2026-01-08
강종구	23.60%	3,790,435	+0.11%	- 특별관계자 장내매수에 따른 보유주식 변동	일반	2025-12-10
강종구	23.49%	3,771,757	+0.31%	- 특별관계자 장내매수에 따른 보유주식 변동 - 주식보유등에 관한 계약 변경	일반	2025-03-06
강종구	23.18%	3,725,011	+0.02%	- 특별관계자 장내매수에 따른 보유주식 변동	일반	2024-12-30
강종구	23.16%	3,720,511	+0.26%	- 특별관계자 장내매수에 따른 보유주식 변동	일반	2024-12-23
강종구	22.90%	3,677,656	+0.09%	- 특별관계자 장내매수에 따른 보유주식 변동 - 주식담보대출 상환	일반	2024-12-10
강종구	22.81%	3,664,133	+0.06%	특별관계자 장내매수에 따른 보유주식 변동	일반	2024-12-09
강종구	22.75%	3,654,333	+0.11%	특별관계자 장내매수에 따른 보유주식 변동	일반	2024-12-06
강종구	22.64%	3,636,809	+0.07%	특별관계자 장내매수에 따른 보유주식 변동	일반	2024-12-05
에스피자산운용	3.59%	593,471	-1.97%	기보유 사모5CB의 조기상환에 따른 변동 보고	약식	2024-11-25
강종구	22.57%	3,624,775	0.00%	보유 주식 등에 대한 계약 내용 변경	일반	2024-09-11
에스피자산운용	5.56%	938,298	+5.56%	5% 이상 보유 신규 보고	약식	2024-07-09
강종구	22.57%	3,624,775	-0.21%	- 특별관계자 변동(추가/해소/구분변경)	일반	2024-04-03
강종구	22.78%	3,667,775	-0.03%	- 특별관계자 보유주식 장내매도	일반	2024-03-08
강종구	22.81%	3,673,775	0.00%	- 최대주주 담보(주식)대출 만기연장 - 특별관계자(키프론바이오) 기존담보(주식)대출상환 및 신규담보(주식) 대출실행	일반	2024-03-04

Major shareholders

Major shareholders (2 people)

Based on 2025 Business report

Name	Shares owned	Ownership	Relationship
강종구外	3,688,435	23.11%	無
셀트리온	1,631,134	10.22%	고객사

Auditors

Analysis date 2026.08.08 20:40

Auditor	Type	Term start	Term end	Tenure	D-day
김원배	Auditor	-	2027.03.29	7 years	D-144
김종연	Auditor	-	2028.03.28	1 years	D-509

Executives

Name	Position	Category	Age	Term end
강종구	대표이사 회장	Inside director	Age 71	D-509
김원	이사	미등기	Age 58	-
김종연	감사	감사	Age 55	D-509
정수용	부사장	Inside director	Age 53	D-877
박선희	전무이사	Inside director	Age 52	D-144
최주영	상무이사	미등기	Age 51	-
김지영	이사	미등기	Age 49	-

DART disclosures

Loading disclosures…

Activism & governance

Board and audit Importance 2 2026.11.04 00:30

바이오톡스텍, 12월 임시주총에 독립이사 선임·준비금 안건 상정

바이오톡스텍은 12월 임시주주총회에서 이정환 독립이사 후보 선임과 준비금 관련 안건을 논의할 예정이다. 이 후보의 임기는 3년이며, 의결권 행사 기준일은 11월 18일이다.

Shareholder perspective 이사 선임과 준비금 안건이 임시주총에서 다뤄져 주주의 의결권 행사와 회사의 자본·이사회 구성에 영향을 줄 수 있다.

Shareholder returns Importance 3 2026.08.10 16:30

바이오톡스텍 임원진 자사주 매입과 주주환원 강화

바이오톡스텍 임원진이 자사주를 잇달아 매입하며 기업가치 회복 의지를 보였다. 회사는 주주서한에서 기업가치 재평가를 위해 자사주 매입·소각 등 주주환원을 강화하겠다고 밝혔다.

Shareholder perspective 경영진의 자사주 매입과 회사의 매입·소각 약속이 결합돼 주주가치 제고 의지를 보여주는 사례입니다.

바이오톡스텍 KOSDAQ

Upcoming shareholder meeting Collapse Upcoming shareholder meeting

Meeting voting results Collapse Meeting voting results

Financial indicators Collapse Financial indicators

Share price history 10 years 5 years 3 years 1 year 3 months 1 week Collapse Share price history

Shareholder distribution Collapse Shareholder distribution

Annual earnings Trend Collapse Annual earnings

Financial statements Collapse Financial statements

Consolidated

Separate

Legacy summary & estimates

Property holdings Collapse Property holdings

Ownership structure Collapse Ownership structure

Corporate shareholders Collapse Corporate shareholders

Business report analysis Collapse Business report analysis

사업 개요

주요 매출원

원가 구조 / 비용 특성

자회사

차입 구조

Articles of incorporation analysis Collapse Articles of incorporation analysis

주주친화

주주비친화

기타 주목 조항

Board of directors

Auditors

Shareholder meetings and dividends

Third-party allotment limit by board resolution alone

Compensation basis

Executive compensation Collapse Executive compensation

Controlling shareholders Collapse Controlling shareholders

Holders of 5% or more Collapse Holders of 5% or more

Major shareholders Collapse Major shareholders

Major shareholders (2 people)

Auditors Collapse Auditors

Executives Collapse Executives

DART disclosures Collapse DART disclosures

Activism & governance Collapse Activism & governance

바이오톡스텍, 12월 임시주총에 독립이사 선임·준비금 안건 상정

바이오톡스텍 임원진 자사주 매입과 주주환원 강화

Upcoming shareholder meeting

Meeting voting results

Financial indicators

Share price history

Shareholder distribution

Annual earnings Trend

Financial statements

Property holdings

Ownership structure

Corporate shareholders

Business report analysis

Articles of incorporation analysis

Executive compensation

Controlling shareholders

Holders of 5% or more

Major shareholders

Auditors

Executives

DART disclosures

Activism & governance